Patent details

EP2178562 Title: Synergistic combinations of vr-1 antagonists and cox-2 inhibitors

Basic Information

Publication number:
EP2178562
PCT Application Number:
EP2008059296
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP087751194
PCT Publication Number:
WO2009010529
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
Synergistic combinations of vr-1 antagonists and cox-2 inhibitors
French Title of Invention:
Combinaisons synergistiques comprenants des antagonistes de VR-1 et des inhibiteurs de COX-2
German Title of Invention:
Synergistische Kombinationen aus VR-1 Antagonisten und COX-2 Inhibitoren
SPC Number:

Dates

Filing date:
16/07/2008
Grant date:
23/08/2017
EP Publication Date:
28/04/2010
PCT Publication Date:
22/01/2009
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
23/08/2017
EP B1 Publication Date:
23/08/2017
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
16/07/2018
Expiration date:
16/07/2028
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
23/08/2017
 
 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Inventor

1

Name:
LILLEY, Elliot
Address:
United Kingdom (GB)

2

Name:
NASH, Mark
Address:
United Kingdom (GB)

3

Name:
SOHAL, Bindi
Address:
United Kingdom (GB)

4

Name:
FOX, Alyson
Address:
United Kingdom (GB)

Priority

Priority Number:
07112679
Priority Date:
18/07/2007
Priority Country:
European Patent Office (EPO) (EP)

Classification

IPC classification:
A61K 31/4418; A61K 31/517; A61K 45/06; A61P 29/00;

Publication

European Patent Bulletin

Issue number:
201734
Publication date:
23/08/2017
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/11/2018 Outgoing Correspondence 1